OCI court-appointed independent non-exec directors continue review of NNS cash offer

Key highlights
  • Court-appointed Directors were appointed by the Enterprise Chamber in January 2026 with a special mandate to assess the proposed OCI–Orascom transaction and protect stakeholders, particularly minority shareholders.
  • Under the Enterprise Court’s orders they are the only persons authorised to place approval of any transaction with Orascom on the agenda of an Extraordinary General Meeting.
  • They welcome NNS’s voluntary all-cash offer as a cash alternative for shareholders and consider its adequacy relevant to resolving the impasse around the proposed transaction.
  • They have not concluded their assessment, will not yet authorise convening an EGM, and intend to finalise their assessment by the end of June 2026.

Mandate and independence

The Court-appointed Directors were appointed by the Enterprise Chamber of the Amsterdam Court of Appeal in January 2026 as non-executive directors with a special mandate. That mandate requires them to independently assess the preparation of the proposed transaction between OCI and Orascom and to ensure the OCI Board fulfils its obligations towards all stakeholders, in particular minority shareholders. Pursuant to the Enterprise Court’s orders, the Court-appointed Directors are the only persons authorised to place the approval of any such transaction with Orascom on the agenda of an Extraordinary General Meeting. In carrying out their mandate, the Court-appointed Directors operate fully independently from the OCI’s controlling shareholder.

Assessment of the NNS offer

The Court-appointed Directors confirm they are continuing to consider the voluntary all-cash offer from NNS. They say the offer would provide a cash alternative for shareholders who do not wish to, or cannot, roll over into Orascom following the proposed OCI–Orascom transaction, and that the adequacy of the offer is a relevant consideration in their ongoing assessment of whether the proposed transaction can be presented to shareholders in a manner that properly addresses stakeholder positions.

Next steps

At this point the Court-appointed Directors have not concluded their assessment and are not yet in a position to authorise convocation of an Extraordinary General Meeting to approve the proposed transaction. They will continue to assess the offer and remain committed to working constructively with the Board, aiming to finalise their assessment by the end of June 2026.

Source: OCI

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

28 September 2026
OCI Global H1 2026 results and strategic progress

Net profit USD 1m; sold ammonia distribution and monetized Methanex; OCI Nitrogen impaired and facing margin pressure; held‑for‑sale net cash USD 1.05bn; NNS offer and Orascom deal progressing.

1 July 2026
OCI recommends NNS EUR 4.10 all-cash offer; court-appointed directors consent to convene EGM for Orascom vote

Board (excluding Nassef and Nadia Sawiris) backs NNS cash offer and court-appointed directors agree to convene an EGM to approve the Orascom transaction, conditional on NNS declaring and settling the offer.

24 June 2026
OCI confirms NNS intends EUR 4.10 per‑share voluntary cash offer

NNS plans a voluntary all‑cash offer at EUR 4.10 cum dividend per share; OCI board (excluding court‑appointed members) backs a cash option tied to the Orascom combination.

16 March 2026
OCI Global H2 and FY 2025 Unaudited Results

Geopolitical tensions raise gas costs, impacting nitrogen production. OCI divests assets, plans merger with Orascom. Court halts shareholder vote pending inquiry. Revenue and EBITDA decline.

9 December 2025
OCI Global Q3 2025 Update

OCI sells ammonia business, plans merger with Orascom, and reports financials. Beaumont project nears completion; strategic review yields $11.6B, with $7B distributed to shareholders.